Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of DaxibotulinumtoxinA for cervical dystonia
2018-000446-19Phase 3Completed
- Sponsor
- Revance Therapeutics
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in cervical dystonia (CD) (3 arms), sponsored by Revance Therapeutics. Started Sep 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on 2018-000446-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000446-19.